NEW YORK, June 7, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alexion Pharmaceuticals, Inc. ("Alexion" or the Company) (NASDAQ: ALXN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
[Click here to join a class action]
The investigation concerns whether Alexion and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 6, 2016, post-market, Alexion announced that Soliris, the Company's treatment for the neuromuscular disease myasthenia gravis, failed to meet its primary goal in a final-stage trial. In a Phase 3 clinical study, patients taking the drug did not report statistically significant changes in the daily activities they could perform after 26 weeks of treatment when compared to those on a placebo.
On this news, Alexion stock has fallen as much as $18.80, or 12.13%, to $136.19 during intraday trading on June 7, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
SOURCE Pomerantz LLP
No comments:
Post a Comment